Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Stock Information for Marvel Biosciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marvel Biosciences Corp.

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.